Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors - Concepedia

Concepedia

Publication | Closed Access

Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

767

Citations

21

References

2015

Year

Amita Patnaik, Soonmo Peter Kang, Drew Rasco, Kyriakos P. Papadopoulos, Jeroen Elassaiss‐Schaap, Muralidhar Beeram, Ronald Drengler, Cong Chen, Lon Smith, Guillermo Espino,

Clinical Cancer Research

Abstract

Pembrolizumab was well tolerated and associated with durable antitumor activity in multiple solid tumors. The lowest dose with full potential for antitumor activity was 2 mg/kg every 3 weeks.

References

	Year	Citations

Page 1